Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 127831, 11 pages
http://dx.doi.org/10.1155/2014/127831
Review Article

Can Serum Glypican-3 Be a Biomarker for Effective Diagnosis of Hepatocellular Carcinoma? A Meta-Analysis of the Literature

1Department of General Surgery, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430077, China
2Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL 32610, USA
3Department of Rehabilitation, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China
4Department of Medicine and Division of Digestion Disease, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430077, China
5Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong Science and Technology University, Wuhan, Hubei 430030, China

Received 25 June 2014; Revised 21 August 2014; Accepted 8 September 2014; Published 14 October 2014

Academic Editor: Chao Hung Hung

Copyright © 2014 Sheng-Li Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [7 citations]

The following is the list of published articles that have cited the current article.

  • Mohamed El-Far, Mohamed M. Omran, Mohamed A. Abdelrazek, Aya M. Saeed, Khaled Farid, Abdelfattah M. Attallah, and Ahmed A. Attallah, “GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma,” Tumor Biology, vol. 37, no. 9, pp. 12571–12577, 2016. View at Publisher · View at Google Scholar
  • Adam B. Elfant, Thomas A. Judge, Sachin Mohan, Navjot Grewal, and Shaffer R.S. Mok, “A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma,” Journal of Gastrointestinal Oncology, vol. 7, no. 4, pp. 570–579, 2016. View at Publisher · View at Google Scholar
  • Paul Clark, “Serum markers for hepatocellular carcinoma,” Clinical Liver Disease, vol. 8, no. 2, pp. 29–33, 2016. View at Publisher · View at Google Scholar
  • Zhi-Ping Liu, “Identifying network-based biomarkers of complex diseases from high-throughput data,” Biomarkers in Medicine, 2016. View at Publisher · View at Google Scholar
  • Yukihiro Haruyama, and Hiroaki Kataoka, “Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 22, no. 1, pp. 275–283, 2016. View at Publisher · View at Google Scholar
  • Adriana Unić, Lovorka Derek, Marko Duvnjak, Leonardo Patrlj, Mislav Rakić, Milan Kujundžić, Vesna Renjić, Nikola Štoković, Petra Dinjar, Anita Jukic, and Ivica Grgurević, “Diagnostic specificity and sensitivity of PIVKAII, GP3, CSTB, SCCA1 and HGF for the diagnosis of hepatocellular carcinoma in patients with alcoholic liver cirrhosis,” Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, vol. 55, no. 3, pp. 355–362, 2017. View at Publisher · View at Google Scholar
  • Taher El-Demerdash, Wael Wahid Mayah, Sherif El-Saadany, Mohammed Hassanien, Nehal Elmashad, Eman Ahmed Basha, Amal Helmy, Boshra El-Sayed Hussein, and Mahmoud Ali Fouad, “Diagnostic value of Glypican-3 for hepatocellular carcinomas,” Asian Pacific Journal of Cancer Prevention, vol. 19, no. 3, pp. 811–817, 2018. View at Publisher · View at Google Scholar